All In Biotech

Drug Trial Radar · NCT04976634

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

730

Planned (sponsor's estimate)

Start

Aug 18, 2021

Primary completion

Mar 22, 2027

Study completion Mar 22, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

Conditions

  • Neoplasm Malignant

Interventions

  • PembrolizumabDrug

    Pembrolizumab 400 mg administered Q6W via IV infusion

  • BelzutifanDrug

    Belzutifan 120 mg administered QD via oral tablet

  • LenvatinibDrug

    Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm 1: Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)Time frame: Up to approximately 21 days
  2. Arm 1: Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 67 months
  3. Arm 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 67 months
  4. Confirmed Objective Response Rate (ORR) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 67 months

Locations

57 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047)

    Tucson, Arizona

  • City of Hope Comprehensive Cancer Center ( Site 5002)

    Duarte, California

  • Cedars-Sinai Medical Center ( Site 5045)

    Los Angeles, California

  • UCSF Medical Center at Mission Bay ( Site 5021)

    San Francisco, California

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 5013)

    New Haven, Connecticut

  • Sibley Memorial Hospital ( Site 5051)

    Washington D.C., District of Columbia

  • University of Florida College of Medicine ( Site 5015)

    Gainesville, Florida

  • Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 5048)

    Baltimore, Maryland

  • Brigitte Harris Cancer Pavilion ( Site 5055)

    Detroit, Michigan

  • Memorial Sloan Kettering Cancer Center ( Site 5050)

    New York, New York

  • Duke Cancer Institute ( Site 5026)

    Durham, North Carolina

  • University of Texas MD Anderson Cancer Center-Gastrointestinal Medical Oncology ( Site 5049)

    Houston, Texas

  • Inova Schar Cancer Institute ( Site 5039)

    Fairfax, Virginia

  • Blue Ridge Cancer Care ( Site 5053)

    Roanoke, Virginia

  • Northwest Medical Specialties, PLLC ( Site 5025)

    Tacoma, Washington

  • University of Wisconsin Hospitals and Clinics ( Site 5037)

    Madison, Wisconsin

  • Gosford Hospital-Oncology Trials ( Site 4004)

    Gosford, New South Wales, Australia

  • Westmead Hospital-Department of Medical Oncology ( Site 4001)

    Westmead, New South Wales, Australia

  • Northern Hospital-Department of Medical Oncology ( Site 4003)

    Epping, Victoria, Australia

  • Cabrini Hospital - Malvern-Cabrini Institute ( Site 4000)

    Malvern, Victoria, Australia

  • Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 1003)

    Namur, Belgium

  • Antwerp University Hospital-Oncology ( Site 1002)

    Edegem, Antwerpen, Belgium

  • Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1001)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • UZ Leuven ( Site 1000)

    Leuven, Vlaams-Brabant, Belgium

  • AZ Delta vzw ( Site 1004)

    Roeselare, West-Vlaanderen, Belgium

  • Centro Investigación del Cáncer James Lind ( Site 3107)

    Temuco, Araucania, Chile

  • Clínica Puerto Montt ( Site 3110)

    Port Montt, Los Lagos Region, Chile

  • FALP-UIDO ( Site 3102)

    Santiago, Region M. de Santiago, Chile

  • Oncovida ( Site 3108)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 3100)

    Santiago, Region M. de Santiago, Chile

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1103)

    Rennes, Brittany Region, France

  • CHU Besançon-Medical oncology ( Site 1101)

    Besançon, Doubs, France

  • CHU Brest Cavale Blanche ( Site 1107)

    Brest, Finistere, France

  • Institut Regional du Cancer Montpellier ( Site 1106)

    Montpellier, Herault, France

  • Hôpital Beaujon-Oncologie Digestive ( Site 1104)

    Clichy, Île-de-France Region, France

  • Centre Hospitalier Universitaire de Grenoble-Medical Oncology ( Site 1105)

    La Tronche, Isere, France

  • Sainte Catherine Institut du Cancer Avignon Provence ( Site 1108)

    Avignon, Vaucluse, France

  • Rambam Health Care Campus-Oncology ( Site 1300)

    Haifa, Israel

  • Hadassah Medical Center-Oncology ( Site 1303)

    Jerusalem, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 1302)

    Ramat Gan, Israel

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.